# Forensic Dossier: Study Forensics: Rapamycin for human longevity — promise vs proof

**Run ID:** `full27_study-forensics-031_Claude_Haiku_7d2d73`  
**Task:** study-forensics-031 | study_forensics | hard | study_forensics  
**Timestamp:** 2026-04-08T08:21:13.623456+00:00  
**Task Family:** mechanism_vs_evidence  
**Trap Type:** strong_preclinical_weak_human  
**Ambiguity:** medium  

## Executive Summary

**Agents tested:** Claude Haiku
**Winner:** Claude Haiku — **40.0/100** (margin: 0.0)
**Failure modes:** named_not_explained, unsupported_conclusion, wrong_answer
**Forensic flags:** 3
**Consistency findings:** 6
**Answer convergence:** all agents agree

## Score Matrix

| Agent | Correctness | Support Strength | Structural Reaso | Assumption Disci | Uncertainty Hand | Alternative Hypo | Self Monitoring  | Insight Depth | Mechanism Qualit | Communication Ef | **Total** |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Claude Haiku | 0.0/30 | 0.0/8 | 4.8/8 | 4.8/6 | 3.9/6 | 6.0/6 | 6.4/8 | 8.0/8 | 1.5/10 | 8.5/10 | **40.0/100** |

## Study Forensics Audit

### Claude Haiku

**Classification:** `solid` [x] (gold: `mechanism_vs_evidence`)
**Finding Recall:** 100%
**Matched Findings:** mechanism_not_demonstrated, decorative_uncertainty
**Extra Findings:** cautious_scope_control, none_or_minor, conclusion_exceeds_results, correlation_as_causation

## Reasoning Integrity Audit

### Claude Haiku
**Classification:** Correct and well-supported
**Load-bearing steps:** 0 / 7

## Mechanism Analysis

### Claude Haiku
| Aspect | Status |
|--------|--------|
| Concept named | :white_check_mark: effect |
| Mechanism described | :x: (0 sentence(s)) |
| Grounded to case | :x: (0 sentence(s)) |

**Missing:** mechanism not described, mechanism not grounded to case data

## Grounding Audit

### Claude Haiku
Conclusion claims: 1
- Direct support: 0
- Indirect support: 0
- Unsupported: 1
- Contradicted: 0

**Unsupported claims:**
- "solid"


## Forensic Flags

### Claude Haiku

- **[MAJOR]** `well_reasoned_wrong`: Wrong answer but structured reasoning — may have a subtle logic error
  - `final_answer`: "solid"
- **[MODERATE]** `unsupported_conclusion_claims`: 1/1 conclusion claims lack step support
  - `final_answer`: "solid"
- **[MODERATE]** `ungrounded_mechanism`: Mechanism named/described but not connected to case-specific data
  - `(mechanism analysis)`: "effect"


## Evidence Map

### Claude Haiku

**Correctness:** 0.0/30
  - (+) `final_answer`: "solid"
    _Agent's answer for correctness check_
  - Note: No match (got: solid)

**Support Strength:** 0.0/8
  - (-) `final_answer`: "solid"
    _Conclusion not supported by steps_
  - Note: Support classification: 0 load-bearing, 0 supporting, 0 mentioned / 7
  - Note: Reasoning graph: conclusion not well grounded

**Structural Reasoning:** 4.8/8
  - (+) `steps[1]`: "Checked for mechanism-vs-evidence issues: The text does NOT claim the mouse mechanism (mTOR inhibition) directly transla"
    _Most informative reasoning step_
  - Note: 7 reasoning steps
  - Note: Low step utility: 0/7 steps contribute

**Assumption Discipline:** 4.8/6
  - (+) `assumptions[2]`: "The trial's primary endpoint (abdominal fat reduction) and secondary endpoint (lean muscle) are appropriate proxies for "
    _Most substantive assumption_
  - Note: 5/5 substantive assumptions

**Uncertainty Handling:** 3.9/6
  - (+) `uncertainties[1]`: "Whether the human trial's failure to reduce abdominal fat is truly the most relevant endpoint for assessing anti-aging e"
    _Most substantive uncertainty_
  - (+) `confidence`: "confidence: 0.92"
    _Stated confidence level_
  - Note: 3 uncertainties (3 substantive)
  - Note: Confidence 0.92

**Alternative Hypothesis Quality:** 6.0/6
  - (+) `alternative_hypotheses[0]`: "Overclaim: Could argue the text implies rapamycin *might* work in humans by mentioning mouse data first, but the text ex"
    _Most substantive alternative hypothesis_
  - Note: 2 alternative hypotheses considered
  - Note: 2/2 include rejection reasoning

**Self Monitoring Quality:** 6.4/8
  - (+) `self_check[2]`: "Did I verify the causal structure? Yes — the text does not claim rapamycin causes aging slowdown in humans; it reports a"
    _Most substantive self-verification step_
  - Note: 5 self-check items
  - Note: Self-check quality: 1 deep, 4 arithmetic, 0 fluff

**Mechanism Quality:** 1.5/10
  - Note: Names concept but does not describe mechanism

**Communication Efficiency:** 8.5/10
  - Note: Signal density: 0.72, 561 words

**Insight Depth:** 8.0/8
  - Note: Key insights: 2 full / 2


## Failure Analysis

### Claude Haiku

**CRITICAL:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Answer does not match expected 'mechanism_vs_evidence'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MAJOR:**
- **Wrong Answer** `[HIGH CONFIDENCE]`: Study classification incorrect: expected 'mechanism_vs_evidence', detected 'solid'
  - `final_answer`: "solid"
  - _Impacts: correctness_

**MODERATE:**
- **Unsupported Conclusion** `[MEDIUM CONFIDENCE]`: Final answer lacks load-bearing or supporting step grounding
  - `final_answer`: "solid"
  - _Impacts: support_strength_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Names the phenomenon but does not explain the causal mechanism
  - `final_answer`: "solid"
  - _Impacts: mechanism_quality_
- **Named Not Explained** `[MEDIUM CONFIDENCE]`: Named concept(s) ['effect'] but mechanism not described
  - _Impacts: mechanism_quality, insight_depth_


## Consistency & Grounding Audit

### Claude Haiku

- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 1 has low overlap with final answer (0/9 content words)
  - `key_claims[0]`: "The text maintains a clear epistemic boundary between mouse efficacy and human efficacy"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 2 has low overlap with final answer (0/11 content words)
  - `key_claims[1]`: "The human trial is presented as negative evidence (failed primary endpoint, no aging biomarker testi"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 3 has low overlap with final answer (0/8 content words)
  - `key_claims[2]`: "Expert consensus is accurately represented: no clinical evidence for anti-aging in humans"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 4 has low overlap with final answer (0/9 content words)
  - `key_claims[3]`: "The text does not claim rapamycin slows aging in people, despite enthusiasm for off-label use"
- **[WARN]** `[HEURISTIC]` `answer_claim_alignment`: Key claim 5 has low overlap with final answer (0/5 content words)
  - `key_claims[4]`: "Risks are appropriately flagged for vulnerable populations"
- **[WARN]** `[MEDIUM CONFIDENCE]` `mechanism_gap`: Phenomenon is named but causal mechanism is not explained
  - `final_answer`: "solid"


## Agent Profiles

### Claude Haiku (claude-haiku-4-5-20251001)
**Parse OK:** True | **Latency:** 11162ms

**Final Answer:** solid

**Confidence:** 0.92

**Assumptions:**
- The mouse lifespan extension data (10-25%) is accurately reported and represents genuine replication across labs
- The human trial described is indeed 'well-designed' as stated
- The trial's primary endpoint (abdominal fat reduction) and secondary endpoint (lean muscle) are appropriate proxies for aging effects
- The text accurately represents expert consensus on current evidence
- Off-label use of rapamycin does carry the risks mentioned for the populations cited

**Reasoning Steps:**
1. Identified the core claim structure: mouse data → human enthusiasm → human trial results → expert caution
2. Checked for mechanism-vs-evidence issues: The text does NOT claim the mouse mechanism (mTOR inhibition) directly translates to humans without evidence. It explicitly notes the human trial 'failed to reduce abdominal fat' and 'did not test whether the drug slows biological aging'
3. Checked for correlation-vs-causation: The text distinguishes between lifespan extension in mice (established) and aging effects in humans (not established). No causal claims about human aging are made
4. Checked for overclaim: The text explicitly states 'no clinical evidence yet shows rapamycin slows aging in people' — this is a clear epistemic boundary
5. Checked for decorative uncertainty: Uncertainty language is substantive here. The text doesn't say 'more research needed' while claiming efficacy; it says the trial 'failed' its primary goal and 'did not test' aging
6. Checked for confounders: The text doesn't make causal claims about why the human trial failed, so confounder analysis is not applicable
7. Verified the cautionary framing: Experts are quoted as cautious, and risks are specified (active cancer, off-label use)

**Key Claims:**
- The text maintains a clear epistemic boundary between mouse efficacy and human efficacy
- The human trial is presented as negative evidence (failed primary endpoint, no aging biomarker testing)
- Expert consensus is accurately represented: no clinical evidence for anti-aging in humans
- The text does not claim rapamycin slows aging in people, despite enthusiasm for off-label use
- Risks are appropriately flagged for vulnerable populations

**Alternative Hypotheses:**
- Overclaim: Could argue the text implies rapamycin *might* work in humans by mentioning mouse data first, but the text explicitly contradicts this with trial failure and expert caution
- Mechanism-vs-evidence: Could argue the mTOR pathway description sets up false expectations, but the text immediately pivots to human evidence and finds it lacking

**Uncertainties:**
- Whether the mouse lifespan studies are truly as robust as stated (I'm taking the text at face value)
- Whether the human trial's failure to reduce abdominal fat is truly the most relevant endpoint for assessing anti-aging effects (the text acknowledges this limitation by noting the trial 'did not test whether the drug slows biological aging')
- The specific risks of off-label rapamycin use beyond those mentioned; the text cites active cancer but may not be exhaustive

**Self-Verification:**
- Did I overdetect problems? No — I initially looked for mechanism-vs-evidence but the text explicitly avoids this trap by testing in humans and reporting failure
- Did I miss overclaiming? No — the text is careful to separate mouse data from human evidence and explicitly states the absence of clinical evidence for aging effects
- Did I verify the causal structure? Yes — the text does not claim rapamycin causes aging slowdown in humans; it reports a trial that failed to show the expected effects
- Is the cautionary tone appropriate? Yes — given the gap between mouse and human data, the expert caution is well-calibrated
- Could the text be clearer? Marginally — it could emphasize that the mouse lifespan extension is not yet explained mechanistically in humans, but this is implicit

**Dimension Scores:**
- Correctness: 0.0/30 `..........`
- Support Strength: 0.0/8 `..........`
- Structural Reasoning: 4.8/8 `######....`
- Assumption Discipline: 4.8/6 `########..`
- Uncertainty Handling: 3.9/6 `######....`
- Alternative Hypothesis Quality: 6.0/6 `##########`
- Self Monitoring Quality: 6.4/8 `########..`
- Insight Depth: 8.0/8 `##########`
- Mechanism Quality: 1.5/10 `#.........`
- Communication Efficiency: 8.5/10 `########..`


## Final Verdict

**Solo run: Claude Haiku** scored **40.0/100**.

**Best per dimension:**
- Correctness: Claude Haiku (0.0/30)
- Support Strength: Claude Haiku (0.0/8)
- Structural Reasoning: Claude Haiku (4.8/8)
- Assumption Discipline: Claude Haiku (4.8/6)
- Uncertainty Handling: Claude Haiku (3.9/6)
- Alternative Hypothesis Quality: Claude Haiku (6.0/6)
- Self Monitoring Quality: Claude Haiku (6.4/8)
- Insight Depth: Claude Haiku (8.0/8)
- Mechanism Quality: Claude Haiku (1.5/10)
- Communication Efficiency: Claude Haiku (8.5/10)

**Latency vs Quality:**

| Agent | Latency | Score | Points/sec |
|-------|---------|-------|------------|
| Claude Haiku | 11.2s | 40.0/100 | 3.6 |

Failure modes observed: named_not_explained, unsupported_conclusion, wrong_answer.
